Biodesix (BDSX) Equity Average (2019 - 2026)

Biodesix (BDSX) has reported Equity Average for 8 consecutive years, with $3.3 million the latest figure, recorded in Q1 2026.

• Equity Average for Q1 2026 came in at $3.3 million, down 79.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.3 million (down 79.12% YoY), and the FY2025 annual result was $9.2 million, down 27.68% from the prior year.
• Equity Average was $3.3 million for Q1 2026 at Biodesix, up from -$2.1 million in the prior quarter.
• Over five years, Equity Average peaked at $32.1 million in Q3 2024 and troughed at -$4.2 million in Q3 2023.
• Average Equity Average over 5 years is $8.0 million, with a median of $6.1 million recorded in 2025.
• Year-over-year, Equity Average tumbled 276.99% in 2023 and soared 3563.77% in 2025.
• Over 5 years, Equity Average stood at $8.9 million in 2022, then sank by 82.3% to $1.6 million in 2023, then soared by 1454.98% to $24.4 million in 2024, then tumbled by 108.59% to -$2.1 million in 2025, then surged by 259.23% to $3.3 million in 2026.
• Per Business Quant data, the three most recent Equity Average figures were $3.3 million in Q1 2026, -$2.1 million in Q4 2025, and -$292000.0 in Q3 2025.